Pharmetheus, founded in 2012, began its growth trajectory under the leadership of Peter Milligan, who became CEO in 2019. With his experience at companies like Pfizer and in-depth knowledge of the pharmacometrics field, he helped grow the company to a leading position, serving a diverse portfolio of pharmaceutical clients and contributing to drug development through its expertise in quantitative approaches.
The Board of Directors has clear expectations on the newly appointed CEO:
“We have been looking for a CEO to lead Pharmetheus’ journey to elevate its market position. Jonas’ previous experience from entering complex environments and taking companies to the next level will make sure these expectations are met,” says Magnus Forsbrand, Chairman of the Board.
Pharmetheus new CEO, Jonas Möller
With the appointment of Jonas Möller, Pharmetheus looks to leverage his extensive experience with consultancies and specialists to further strengthen the company’s expertise and growth:
“Throughout my career, I have had the opportunity to work with organizations where specialist expertise is at the heart of the business. It is always highly motivating to collaborate with people who are true specialists in their field, and this is one of the things that makes Pharmetheus especially exciting to me. I want to recognize the strong foundation built by Peter and the Pharmetheus team over many years,” says Möller.
